We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals

128 hedge funds and large institutions have $188M invested in Zentalis Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

641% more capital inflows, than outflows

Capital inflows: $94.1M | Capital outflows: $12.7M

167% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $484K

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

41% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 32

27.84% more ownership

Funds ownership: 66.78% → 94.62% (+28%)

10% more funds holding

Funds holding: 116 → 128 (+12)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
128
Holders Change
+12
Holders Change %
+10.34%
% of All Funds
1.56%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
26
Increased
45
Reduced
32
Closed
13
Calls
$1.29​M
Puts
$484​K
Net Calls
+$806​K
Net Calls Change
-⁠$1.94​M

ZNTL Hedge Fund Activity: Q3 2026 in Review

128 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2026, worth a combined $188M — down 18% from $230M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ZNTL positions and 13 closed out — a net gain of 13 holders — while 45 added to existing stakes and 32 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $14.4M. The largest seller was D.E. Shaw & Co, cutting an estimated $1.12M.

  • 128 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2026, up from 116 in Q2 2026.
  • Funds reported $188M of Zentalis Pharmaceuticals stock for Q3 2026, down 18% quarter-over-quarter.
  • 26 funds opened new Zentalis Pharmaceuticals positions in Q3 2026 and 13 closed out, a net change of +13 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q3 2026 was NEA Management Company, an estimated $14.4M added.
  • The largest Zentalis Pharmaceuticals seller in Q3 2026 was D.E. Shaw & Co, an estimated $1.12M sold.

Based on aggregated 13F filings for Q3 2026.